ASTX295 is an orally active and selective MDM2 antagonist with an IC50 of MDM2-p53 interaction, activates wild-type TP53, and thereby induces the expression of relevant transcriptional targets, leading to cell death. ASTX295 drives the transition of pancreatic cancer cells from senescence to apoptosis and regulates p53 and DNA damage biomarkers. ASTX295 can be used for the research of hematologic malignancies and pancreatic cancer[1][2].
Molecular Weight:
630.53
Purity:
99.81
CAS Number:
[2093449-12-6]
Formula:
C33H34Cl2FNO6
Target:
Apoptosis,Caspase,MDM-2/p53
Application Notes:
MCE Product type: Reference compound1
* VAT and and shipping costs not included. Errors and price changes excepted
